Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but it is also our aim to address other therapeutic areas where our competence and technologies can create value. The main market today is the American market for the treatment of opioid dependence, where Orexo commercialize the product Zubsolv®. Other products are commercialized through selected partners, including sale of Zubsolv outside the US.

Vision

The aim and vision is to develop a growing profitable specialty pharmaceutical company which through its own sales can finance the development of new pharmaceuticals, within several theraputic areas, based on Orexo’s innovative technologies

Read more - Vision, OBJECTIves & strategies

Core Values

“The key to our success can be found in our core values – customer focus, engagement, flexibility and simplicity. Values that characterize our employees’ daily work.”
Nikolaj Sørensen, President and CEO

READ MORE - CEO COMMENTS

Development

Orexo develops improved products by combining well-known and well-documented substances with in-house innovative drug delivery technologies. Orexo is acknowledged as the world leader for sublingual formulation platforms. The sublingual formulation technology is to be found in all our current products. Several important steps were taken in 2016 to develop next generation drug delivery technologies. Development of products in the pipeline is governed by medical need and commercial potential. Orexo’s development model is characterized by lower costs, shorter lead times and lower risk compared to the development of new substances.

Orexo’s development model is characterized by lower costs, shorter lead times and lower risk compared to the development of new substances

READ MORE - PIPELine

Key Market

Orexo’s key market today is the American market for the treatment of opioid dependence using buprenorphine/naloxone. Orexo operates in the market through the commercialization of Zubsolv, which is an effective drug for people with opioid dependence. Dying from an overdose is one of the most common causes of death in the US and the problem has been classified as an epidemic. Several important federal initiatives have been taken to increase access to treatment, and this creates scope for continued strong growth. The main market has a value of around USD 2.4 billion, and in recent years has had an annual growth of approximately 8 percent. Mundipharma, through its network of independent associated companies, has a presence in 48 countries and owns the rights to Zubsolv outside the US.

The American market for treatment of opioid dependence annual growth is expected to grow 10 percent during 2017

READ MORE - KEY MARKET

Products

Orexo has developed four products from idea to patient. The products have proved to be of considerable value for patients worldwide and are commercialized through Orexo or carefully selected partners.

 Product     

 Zubsolv® 

 Abstral®   

 Edluar® 

 Diabact®1

 Indication

 Opioid dependence

Breakthrough cancer pain

Sleeping problems

Diagnosing stomach ulcer bacteria

Commercialization/ Partnership

Several external partners

Market

US/ex US

US/ EU and RoW

Globally

Globally

1 Diabact® is a product that belongs to Kibion, a subsidiary that Orexo sold in 2015

READ MORE- PRODUCTS